BMO Capital Markets Lowers Equinox Gold (EQX) Price Target to C$2.00

Share on StockTwits

Equinox Gold (CVE:EQX) had its target price reduced by BMO Capital Markets from C$2.20 to C$2.00 in a research report report published on Thursday.

Several other analysts have also recently issued reports on the stock. National Bank Financial cut shares of Equinox Gold from an outperform spec overweight rating to a sector perform spec overwgt rating in a research note on Tuesday, February 26th. Raymond James set a C$2.00 price objective on shares of Equinox Gold and gave the company an outperform rating in a research note on Tuesday, February 26th. Finally, CIBC boosted their price objective on shares of Equinox Gold from C$1.30 to C$1.50 in a research note on Monday, January 21st.

Shares of CVE EQX traded down C$0.01 during trading on Thursday, hitting C$1.23. 27,855 shares of the company traded hands, compared to its average volume of 559,866. Equinox Gold has a 1 year low of C$0.85 and a 1 year high of C$1.29. The stock has a market capitalization of $689.13 million and a PE ratio of -7.21. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 19.95.

About Equinox Gold

Equinox Gold Corp. engages in the acquisition, exploration, and development of mineral deposits. The company's principal properties include the Aurizona project covering a total land package of approximately 223,160 hectares located in Maranhão State, Brazil; and the Castle Mountain property situated in California, the United States.

Featured Story: Consumer Price Index (CPI)

Receive News & Ratings for Equinox Gold Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equinox Gold and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Uniti Group  Given New $8.00 Price Target at Deutsche Bank
Uniti Group Given New $8.00 Price Target at Deutsche Bank
Vertex Pharmaceuticals  Downgraded by BidaskClub to Hold
Vertex Pharmaceuticals Downgraded by BidaskClub to Hold
Zacks Investment Research Upgrades Ionis Pharmaceuticals  to “Buy”
Zacks Investment Research Upgrades Ionis Pharmaceuticals to “Buy”
BidaskClub Downgrades DENTSPLY SIRONA  to Hold
BidaskClub Downgrades DENTSPLY SIRONA to Hold
Liberum Capital Reiterates Hold Rating for Smiths Group
Liberum Capital Reiterates Hold Rating for Smiths Group
RWE  Given a €29.50 Price Target at Goldman Sachs Group
RWE Given a €29.50 Price Target at Goldman Sachs Group


© 2006-2019 Ticker Report